Summary
There is uncertain result with regard to the use of inhalation or instillation steroids to prevent bronchopulmonary dysplasia in preterm infants. This meta-analysis was designed to evaluate the efficacy and safety of early airway administration (within 2 days after birth) of corticosteroids and pulmonary surfactant (PS) for preventing bronchopulmonary dysplasia (BPD) in premature infants with neonatal respiratory distress syndrome (NRDS). The related studies were retrieved in PubMed, EMBASE, the Cochrane Library, Clinical Trial, CNKI, Wanfang and VIP Database from inception to August 2018. Two reviewers independently screened the studies to ensure that all patients with diagnosis of NRDS were enrolled to studies within 1 day after birth, assessed the quality of included studies by GRADEpro system and extracted the data for review. The meta-analysis was performed by RevMan 5.2 software. A subgroup analysis about inhaled corticosteroid (ICS) delivery method was made between ICS inhalation subgroup [inhalation of ICS by nebulizer or metered dose inhaler (MDI)] and ICS intratracheal instillation subgroup (PS used as a vehicle). Eight randomized controlled trials were enrolled in the meta-analysis, 5 trials of which stated the randomized method, grouping and blinded method, and the follow-up procedures were reported. GRADEpro system showed high quality of 4 trials (5 articles), and the rest 4 trials had moderate quality. Meta-analysis showed that the incidence of BPD was decreased in ICS group, the relative risk (RR) was 0.56 (95% CI: 0.42–0.76), and similar trends were found in ICS inhalation subgroup and ICS intratracheal instillation subgroup, with the corresponding RR being 0.58 (95% CI: 0.41–0.82) and 0.47 (95% CI: 0.24–0.95) respectively. ICS could also significantly reduce the mortality risk as compared with placebo control group (RR: 0.67; 95% CI: 0.45–0.99), with RR of ICS inhalation subgroup and ICS intratracheal instillation subgroup being 0.81 (95% CI: 0.34–1.94) and 0.64 (95% CI: 0.41–0.99) respectively. Moreover, the percentage of infants using PS more than one time was lower in ICS group than in the placebo control group, with the RR and 95% CI being 0.55 (95% CI: 0.45–0.67), and that in ICS intratracheal instillation subgroup lower than in ICS inhalation subgroup (RR: 0.56; 95% CI: 0.45–0.69, and RR: 0.35; 95% CI: 0.08–1.52 respectively). There was no significant difference in the incidence of infection or retinopathy of prematurity and neuro-motor system impairment between ICS group and placebo control group, with the corresponding RR being 0.95 (95% CI: 0.59–1.52), 0.92 (95% CI: 0.62–1.38) and 1.13 (95% CI: 0.92–1.39), respectively. It was concluded that early administration of ICS and PS is an effective and safe option for preterm infants with NRDS in preventing BPD and reducing mortality, decreasing the additional PS usage, especially for the ICS intratracheal instillation subgroup. Furthermore, the appropriate dose and duration of ICS, combined use of inhalation or instillation of ICS with PS and the long-term safety of airway administration of corticosteroids need to be assessed in large trials.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Carvalho CG, Silveira RC, Procianoy RS. Ventilator-induced lung injury in preterm infants. Revista Brasileira De Terapia Intensiva, 2013,25(4):319–326
Yeh TF, Lin YJ, Hsieh WS, et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics,1997,100(4):e3–e3
Collaborative Dexamethasone Trial Group. Dexameth-asone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics, 1991,88(3):421–427
Cummings JJ, D’Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med, 1989,320(23):1505–1510
Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics, 2001,108(3):741–748
Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics, 1998,101(5):E7
Avery GB, Fletcher AB, Kaplan M, et al. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics, 1985,75(1):106–111
Yeh TF, Lin YJ, Lin HC, et al. Outcome at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med, 2004,350(13):1304–1313
Grigg J, Arnon S, Jones T, et al. Delivery of therapeutic aerosols to intubated babies. Arch Dis Child, 1992,67(1):25–30
Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med, 1999,340(13):1005–1010
Fujiwara T, Chida S, Watabe Y, et al. Artificial surfactant therapy in hyaline membrane disease. Lancet, 1980,1(8159):55–59
Ferrara TB, Hoekstra RE, Johnson P, et al. Localization of surfactant in neonatal lung after exogenous administration. J Pediatr, 1987,111(3):463–466
Tam D, Von Arnim V, Mckinley GH, et al. Marangoni convection in droplets on superhydrophobic surfaces. J Fluid Mechan, 2009,624:101
Fajardo C, Levin D, Garcia M, et al. Surfactant versus saline as a vehicle for corticosteroid delivery to the lungs of ventilated rabbits. Pediatr Res, 1998,43(4):542–547
Kharasch VS, Sweeney TD, Fredberg J, et al. Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs. Am Rev Respir Dis, 1991,144(4):909–913
Kuo HT, Lin HC, Tsai CH, et al. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J Pediatr, 2010,156(4),537–541.
Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics, 2008,121(5): e1310–e1318
Sadeghnia A, Beheshti BK, Mohammadizadeh M. The effect of inhaled budesonide on the prevention of chronic lung disease in premature neonates with respiratory distress syndrome. Int J Prev Med, 2018,9:15
Yeh TF, Chen CM, Wu SY, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. Am J Respirat Crit Care Med, 2016,193(1):86–95
Zimmerman JJ, Gabbert D, Shivpuri C, et al. Meter-dosed, inhaled beclomethasone initiated at birth to prevent bronchopulmonary dysplasia. Pediatr Crit Care Med, 2000,1(2):140–145
Cao YY, Yao G, Wang Y, et al. Aerosol Inhalation of Budesonide and Pulmonary Surfactant to Prevent Bronchopulmonary Dysplasia. J Pediatr Pharmacy, 2018,24(03):25–29
Ke H, Li ZK, Yu XP, et al. Efficacy of different preparations of budesonide combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome: a comparative analysis. Zhongguo Dang Dai Er Ke Za Zhi (Chinese), 2016,18(5):400–404
Pan J, Chen MW, Ni WQ, et al. Clinical efficacy of pulmonary surfactant combined with budesonide for preventing bronchopulmonary dysplasia in very low birth weight infants. Zhongguo Dang Dai Er Ke Za Zhi (Chinese), 2017,19(2):137–141
Deng LJ, Peng HB, Gong XQ. Effect of budesonide combined with pulmonary surfactant on severe respiratory distress syndrome in bronchopulmonary dysplasia. Chin J Neonatol (Chinese), 2017,32(5):361–364
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med, 2010,8(1):18
Bhandari A, Panitch H. An update on the post-NICU discharge management of bronchopulmonary dysplasia. Semin Perinatol, 2018,42(7):471–477
Nagiub M, Kanaan U, Simon D, et al. Risk factors for development of pulmonary hypertension in infants with bronchopulmonary dysplasia: systematic review and meta-analysis. Paediatr Respirat Rev, 2017,23:27–32
Merz U, Kusenbach G, Häusler M, et al. Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. Neonatology, 1999,75(1):46–53
Onland W, Offringa M, van Kaam A. Late (=7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev, 2012,4:CD2311
Venkataraman R, Kamaluddeen M, Hasan SU, et al. Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants: a systematic review and metaanalysis. Pediatr Pulmonol, 2017,52(7):968–975
Zhang ZQ, Zhong Y, Huang XM, et al. Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis with trial sequential analysis. BMC Pulmon Med, 2017,17(1):207
Zeng L, Tian J, Song F, et al. Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis. Arch Dis Child Fetal Neonatal Ed, 2018,103(6):F506–F511
Yu ZW, Zhang JH. Effect of inhaled budesonide on surfactant protein expression in asthmatic mice. Allergy Asthma Proc. 2008,29(5):486–492
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhong, Yy., Li, Jc., Liu, Yl. et al. Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis. CURR MED SCI 39, 493–499 (2019). https://doi.org/10.1007/s11596-019-2064-9
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-019-2064-9